METCI experienced a dramatic deterioration in operating cash flow alongside substantial balance sheet expansion, indicating significant operational stress despite asset growth.
The company's operating cash flow collapsed to just $2.0M from $112.7M in the prior year, representing a fundamental shift in cash generation capability that raises immediate liquidity concerns. This cash flow decline occurred despite total assets growing substantially to $1.1B, suggesting the company may be investing heavily in expansion while struggling to maintain operational profitability.
The financial profile shows a company under significant operational strain, with operating cash flow nearly disappearing while stockholders' equity grew modestly to $483.6M. Capital expenditures remained elevated at $82.9M despite the cash flow pressures, and SG&A expenses increased meaningfully to $69.4M, suggesting higher operational costs. The combination of dramatically reduced cash generation, lower dividend payments, and substantial asset expansion indicates METCI is in a capital-intensive growth phase that has severely impacted near-term cash flow performance.
Operating cash flow fell 98.3% — earnings quality concerns; investigate working capital changes and non-cash items.
Net interest income declined 87.8% — margin compression from rate changes or funding cost increases.
Dividends cut 82.4% — significant signal of cash flow stress or capital reallocation priorities.
Asset base grew 69.1% — expansion through organic growth, acquisitions, or capital deployment.
SG&A up 40.7% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Equity base grew 33.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Capex reduced 32.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Current liabilities reduced — improved short-term financial position and working capital health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →